Lipocine Announces Senior Leadership Appointments to Advance its CNS-Focused Pipeline

SALT LAKE CITY, Nov. 3, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating CNS disorders by leveraging its proprietary platform to develop differentiated products, today announced George Nomikos, M.D., Ph.D., has joined Lipocine as Chief Medical Officer and Spyros Papapetropoulos, M.D. Ph.D., has been appointed Lead Director and Chairman of the Board.

Lipocine Inc. recently announced that the U.S. Food and Drug Administration ("FDA") has agreed with the Company's proposal for establishing the efficacy of LPCN 1154 in postpartum depression through a pivotal pharmacokinetic ("PK") bridge study to an approved IV infusion brexanolone via a 505(b)(2) NDA filing. Lipocine recently initiated a pilot PK bridge study (a prelude to a pivotal study required for NDA filing) and expects to report results of the pilot study in the first half of 2023. If approved, LPCN 1154 is expected to be the fastest acting oral option for PPD with potential for out-patient use.

"Consistent with our recently announced new strategy to a focus on developing new treatments for CNS disorders, it is important that Lipocine have a leadership team with the appropriate skillset," said Dr. Mahesh Patel, President and CEO of Lipocine Inc. "I am delighted to welcome Dr. Nomikos as Chief Medical Officer and congratulate Dr. Papapetropoulos on his appointment as Lead Director and Chairman of the Board. George's knowledge in the fields of neurology and psychiatry, both from an academic and industry perspective, will be invaluable as we advance our pipeline of CNS candidates. In addition, Spyros' executive and BoD tenure in CNS-focused companies combined with his expertise in clinical and translational neurosciences means that he is well qualified to guide the company. We look forward to the contributions these talented individuals will bring to Lipocine and are excited to have them as an integral part of our leadership team."

Dr. Spyros Papapetropoulos commented, "This is an exciting time for Lipocine. The Company has a compelling opportunity to leverage its best-in-class oral delivery technology to develop differentiated treatments for high unmet need neuropsychiatric disorders. I look forward to continue being a part of the Company's renewed CNS focus in my role as Chairman."